Advertisement

Bullous Diseases in Children: A Review of Clinical Features and Treatment Options

  • Brittney Schultz
  • Kristen HookEmail author
Review Article

Abstract

Bullous diseases are uncommon in children; however, as they have the potential to affect quality of life, occasionally have long-term side effects in the setting of scarring processes, and carry a rare risk of underlying malignancy [e.g., with paraneoplastic pemphigus (PNP)], knowledge of their clinical presentation and treatment options is essential. Given the rarity of these conditions, our current state of knowledge is largely derived from case reports and case series, with a paucity of evidence-based recommendations. In this review, we discuss the clinical presentation of and treatment options for linear immunoglobulin A disease, dermatitis herpetiformis, pemphigus vulgaris, pemphigus foliaceus, PNP, bullous pemphigoid, mucus membrane pemphigoid, epidermolysis bullosa acquisita, and inherited epidermolysis bullosa. In general, when these conditions, except for PNP, occur in childhood, they have a better prognosis than when they occur in adults. Clinical, histopathological, and immunologic features frequently overlap, but distinct differences have also been reported, most commonly in clinical presentation. Treatment is often similar to that in adults, although specific considerations are necessary for a pediatric population.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflict of interest

Dr. Schultz and Dr. Hook have no conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Weston WL, Morelli JG, Huff JC. Misdiagnosis, treatments, and outcomes in the immunobullous diseases in children. Pediatr Dermatol. 1997;14(4):264–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Kong YL, Lim YL, Chandran NS. Retrospective study on autoimmune blistering disease in paediatric patients. Pediatr Dermatol. 2015;32(6):845–52.  https://doi.org/10.1111/pde.12684.CrossRefPubMedGoogle Scholar
  3. 3.
    Fine JD. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the national epidermolysis bullosa registry. JAMA Dermatol. 2016;152(11):1231–8.  https://doi.org/10.1001/jamadermatol.2016.2473.CrossRefPubMedGoogle Scholar
  4. 4.
    Ren Z, Hsu DY, Silverberg NB, Silverberg JI. The inpatient burden of autoimmune blistering disease in US children: analysis of nationwide inpatient sample data. Am J Clin Dermatol. 2017;18(2):287–97.  https://doi.org/10.1007/s40257-017-0257-1.CrossRefPubMedGoogle Scholar
  5. 5.
    Jeon IK, On HR, Kim SC. Quality of life and economic burden in recessive dystrophic epidermolysis bullosa. Ann Dermatol. 2016;28(1):6–14.  https://doi.org/10.5021/ad.2016.28.1.6.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Antiga E, Torchia D, Caproni M, Fabbri P. Linear immunoglobulin A bullous dermatosis. Expert Rev Dermatol. 2009;4(5):495–508.CrossRefGoogle Scholar
  7. 7.
    Jabłońska S, Chorzelski TP, Rosinska D, Maciejowska E. Linear IgA bullous dermatosis of childhood (chronic bullous dermatosis of childhood). Clin Dermatol. 1991;9(3):393–401.CrossRefPubMedGoogle Scholar
  8. 8.
    Wojnarowska F, Marsden RA, Bhogal B, Black MM. Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol. 1988;19(5 Pt 1):792–805.CrossRefPubMedGoogle Scholar
  9. 9.
    Yamagami J, Nakamura Y, Nagao K, Funakoshi T, Takahashi H, Tanikawa A, et al. Vancomycin mediates IgA autoreactivity in drug-induced linear IgA bullous dermatosis. J Invest Dermatol. 2018;138(7):1473–80.  https://doi.org/10.1016/j.jid.2017.12.035.CrossRefPubMedGoogle Scholar
  10. 10.
    Ho JC, Ng PL, Tan SH, Giam YC. Childhood linear IgA bullous disease triggered by amoxicillin-clavulanic acid. Pediatr Dermatol. 2007;24(5):E40–3.  https://doi.org/10.1111/j.1525-1470.2007.00438.x.CrossRefPubMedGoogle Scholar
  11. 11.
    Garel B, Ingen-Housz-Oro S, Afriat D, Prost-Squarcioni C, Tétart F, Bensaid B, et al. Drug-induced linear IgA bullous dermatosis: a French retrospective pharmacovigilance study of 69 cases. Br J Clin Pharmacol. 2019;85(3):570–9.  https://doi.org/10.1111/bcp.13827.CrossRefPubMedGoogle Scholar
  12. 12.
    Handley J, Shields M, Dodge J, Walsh M, Bingham A. Chronic bullous disease of childhood and ulcerative colitis. Pediatr Dermatol. 1993;10(3):256–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Wong CS, Arkwright PD, Rieux-Laucat F, Cant AJ, Stevens RF, Judge MR. Childhood linear IgA disease in association with autoimmune lymphoproliferative syndrome. Br J Dermatol. 2004;150(3):578–80.  https://doi.org/10.1111/j.1365-2133.2004.05850.x.CrossRefPubMedGoogle Scholar
  14. 14.
    Polat M, Lenk N, Kürekçi E, Oztaş P, Artüz F, Alli N. Chronic bullous disease of childhood in a patient with acute lymphoblastic leukemia: possible induction by a drug. Am J Clin Dermatol. 2007;8(6):389–91.  https://doi.org/10.2165/00128071-200708060-00010.CrossRefPubMedGoogle Scholar
  15. 15.
    Nantel-Battista M, Al Dhaybi R, Hatami A, Marcoux D, Desroches A, Kokta V. Childhood linear IgA bullous disease induced by trimethoprim-sulfamethoxazole. J Dermatol Case Rep. 2010;4(3):33–5.  https://doi.org/10.3315/jdcr.2010.1053.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Zhao CY, Chiang YZ, Murrell DF. Neonatal autoimmune blistering disease: a systematic review. Pediatr Dermatol. 2016;33(4):367–74.  https://doi.org/10.1111/pde.12859.CrossRefPubMedGoogle Scholar
  17. 17.
    Mintz EM, Morel KD. Treatment of chronic bullous disease of childhood. Dermatol Clin. 2011;29(4):699–700.  https://doi.org/10.1016/j.det.2011.08.013.CrossRefPubMedGoogle Scholar
  18. 18.
    Edwards S, Wojnarowska F. Chronic bullous disease of childhood in three patients of Polynesian extraction. Clin Exp Dermatol. 1990;15(5):367–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Khanna N, Pandhi RK, Gupta S, Singh MK. Response of chronic bullous dermatosis of childhood to a combination of dapsone and nicotinamide. J Eur Acad Dermatol Venereol. 2001;15(4):368.PubMedGoogle Scholar
  20. 20.
    Gläser R, Sticherlin M. Successful treatment of linear IgA bullous dermatosis with mycophenolate mofetil. Acta Derm Venereol. 2002;82(4):308–9.  https://doi.org/10.1080/000155502320323351.CrossRefPubMedGoogle Scholar
  21. 21.
    Talhari C, Mahnke N, Ruzicka T, Megahed M. Successful treatment of linear IgA disease with mycophenolate mofetil as a corticosteroid sparing agent. Clin Exp Dermatol. 2005;30(3):297–8.  https://doi.org/10.1111/j.1365-2230.2005.01741.x.CrossRefPubMedGoogle Scholar
  22. 22.
    Farley-Li J, Mancini AJ. Treatment of linear IgA bullous dermatosis of childhood with mycophenolate mofetil. Arch Dermatol. 2003;139(9):1121–4.  https://doi.org/10.1001/archderm.139.9.1121.CrossRefPubMedGoogle Scholar
  23. 23.
    Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horváth B. Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. Front Immunol. 2018;9:248.  https://doi.org/10.3389/fimmu.2018.00248.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Antiga E, Verdelli A, Calabrò A, Fabbri P, Caproni M. Clinical and immunopathological features of 159 patients with dermatitis herpetiformis: an Italian experience. G Ital Dermatol Venereol. 2013;148(2):163–9.PubMedGoogle Scholar
  25. 25.
    Powell GR, Bruckner AL, Weston WL. Dermatitis herpetiformis presenting as chronic urticaria. Pediatr Dermatol. 2004;21(5):564–7.  https://doi.org/10.1111/j.0736-8046.2004.21509.x.CrossRefPubMedGoogle Scholar
  26. 26.
    Heinlin J, Knoppke B, Kohl E, Landthaler M, Karrer S. Dermatitis herpetiformis presenting as digital petechiae. Pediatr Dermatol. 2012;29(2):209–12.  https://doi.org/10.1111/j.1525-1470.2011.01401.x.CrossRefPubMedGoogle Scholar
  27. 27.
    Barnadas MA. Dermatitis herpetiformis: a review of direct immunofluorescence findings. Am J Dermatopathol. 2016;38(4):283–8.  https://doi.org/10.1097/DAD.0000000000000420.CrossRefPubMedGoogle Scholar
  28. 28.
    Sousa L, Bajanca R, Cabral J, Fiadeiro T. Dermatitis herpetiformis: should direct immunofluorescence be the only diagnostic criterion? Pediatr Dermatol. 2002;19(4):336–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis. J Am Acad Dermatol. 2011;64(6):1027–33.  https://doi.org/10.1016/j.jaad.2010.09.776 (quiz 1033–1024).CrossRefPubMedGoogle Scholar
  30. 30.
    Ermacora E, Prampolini L, Tribbia G, Pezzoli G, Gelmetti C, Cucchi G, et al. Long-term follow-up of dermatitis herpetiformis in children. J Am Acad Dermatol. 1986;15(1):24–30.CrossRefPubMedGoogle Scholar
  31. 31.
    Hervonen K, Salmi TT, Kurppa K, Kaukinen K, Collin P, Reunala T. Dermatitis herpetiformis in children: a long-term follow-up study. Br J Dermatol. 2014;171(5):1242–3.  https://doi.org/10.1111/bjd.13047.CrossRefPubMedGoogle Scholar
  32. 32.
    Cunningham MJ, Zone JJ. Thyroid abnormalities in dermatitis herpetiformis. Prevalence of clinical thyroid disease and thyroid autoantibodies. Ann Intern Med. 1985;102(2):194–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Hervonen K, Viljamaa M, Collin P, Knip M, Reunala T. The occurrence of type 1 diabetes in patients with dermatitis herpetiformis and their first-degree relatives. Br J Dermatol. 2004;150(1):136–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45(3):420–34.  https://doi.org/10.1067/mjd.2001.114733.CrossRefPubMedGoogle Scholar
  35. 35.
    Albers LN, Zone JJ, Stoff BK, Feldman RJ. Rituximab treatment for recalcitrant dermatitis herpetiformis. JAMA Dermatol. 2017;153(3):315–8.  https://doi.org/10.1001/jamadermatol.2016.4676.CrossRefPubMedGoogle Scholar
  36. 36.
    Bjarnason B, Flosadóttir E. Childhood, neonatal, and stillborn pemphigus vulgaris. Int J Dermatol. 1999;38(9):680–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Peterman CM, Vadeboncoeur S, Schmidt BA, Gellis SE. Pediatric pemphigus herpetiformis: case report and review of the literature. Pediatr Dermatol. 2017;34(3):342–6.  https://doi.org/10.1111/pde.13152.CrossRefPubMedGoogle Scholar
  38. 38.
    Schoch JJ, Boull CL, Camilleri MJ, Tollefson MM, Hook KP, Polcari IC. Transplacental transmission of pemphigus herpetiformis in the setting of maternal lymphoma. Pediatr Dermatol. 2015;32(6):e234–7.  https://doi.org/10.1111/pde.12649.CrossRefPubMedGoogle Scholar
  39. 39.
    Bruckner AL, Fitzpatrick JE, Hashimoto T, Weston WL, Morelli JG. Atypical IgA/IgG pemphigus involving the skin, oral mucosa, and colon in a child: a novel variant of IgA pemphigus? Pediatr Dermatol. 2005;22(4):321–7.  https://doi.org/10.1111/j.1525-1470.2005.22408.x.CrossRefPubMedGoogle Scholar
  40. 40.
    Neethu KC, Rao R, Balachandran C, Pai S. Juvenile IgA pemphigus: a case report and review of literature. Indian J Dermatol Venereol Leprol. 2016;82(4):439–42.  https://doi.org/10.4103/0378-6323.181467.CrossRefPubMedGoogle Scholar
  41. 41.
    Palleschi GM, Giomi B, Giacomelli A. Juvenile pemphigus vegetans of the glans penis. Acta Derm Venereol. 2004;84(4):316–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Tani N, Sugita K, Ishii N, Wakumoto K, Hashimoto T, Yamamoto O. Juvenile pemphigus vulgaris manifesting as vegetating skin lesions. Clin Exp Dermatol. 2019;44(5):559–61.  https://doi.org/10.1111/ced.13796.CrossRefPubMedGoogle Scholar
  43. 43.
    Leventhal JS, Haberland CM, Cowper SE, Tomayko MM. Image gallery: juvenile autoimmune pemphigus presenting with diffuse gingival hypertrophy and antibodies against desmocollin 3. Br J Dermatol. 2017;177(5):e226.  https://doi.org/10.1111/bjd.15954.CrossRefPubMedGoogle Scholar
  44. 44.
    Mabrouk D, Ahmed AR. Analysis of current therapy and clinical outcome in childhood pemphigus vulgaris. Pediatr Dermatol. 2011;28(5):485–93.  https://doi.org/10.1111/j.1525-1470.2011.01514.x.CrossRefPubMedGoogle Scholar
  45. 45.
    Asarch A, Gürcan HM, Ahmed AR. A current review of juvenile pemphigus vulgaris: analysis of data on clinical outcomes. Am J Clin Dermatol. 2010;11(1):21–33.  https://doi.org/10.2165/11310380-000000000-00000.CrossRefPubMedGoogle Scholar
  46. 46.
    Baratta A, Camarillo D, Papa C, Treat JR, Payne AS, Rozenber SS, et al. Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF). Pediatr Dermatol. 2013;30(2):240–4.  https://doi.org/10.1111/j.1525-1470.2012.01730.x.CrossRefPubMedGoogle Scholar
  47. 47.
    Beissert S, Werfel T, Frieling U, Böhm M, Sticherling M, Stadler R, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142(11):1447–54.  https://doi.org/10.1001/archderm.142.11.1447.CrossRefPubMedGoogle Scholar
  48. 48.
    Asarch A, Razzaque Ahmed A. Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulin therapy. Pediatr Dermatol. 2009;26(2):197–202.  https://doi.org/10.1111/j.1525-1470.2008.00808.x.CrossRefPubMedGoogle Scholar
  49. 49.
    Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–40.  https://doi.org/10.1016/S0140-6736(17)30070-3.CrossRefPubMedGoogle Scholar
  50. 50.
    Kincaid L, Weinstein M. Rituximab therapy for childhood pemphigus vulgaris. Pediatr Dermatol. 2016;33(2):e61–4.  https://doi.org/10.1111/pde.12744.CrossRefPubMedGoogle Scholar
  51. 51.
    Vinay K, Kanwar AJ, Sawatkar GU, Dogra S, Ishii N, Hashimoto T. Successful use of rituximab in the treatment of childhood and juvenile pemphigus. J Am Acad Dermatol. 2014;71(4):669–75.  https://doi.org/10.1016/j.jaad.2014.05.071.CrossRefPubMedGoogle Scholar
  52. 52.
    Kanwar AJ, Tsuruta D, Vinay K, Koga H, Ishii N, Dainichi T, et al. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J Eur Acad Dermatol Venereol. 2013;27(1):e17–23.  https://doi.org/10.1111/j.1468-3083.2011.04391.x.CrossRefPubMedGoogle Scholar
  53. 53.
    Diaz LA, Sampaio SA, Rivitti EA, Martins CR, Cunha PR, Lombardi C, et al. Endemic pemphigus foliaceus (Fogo Selvagem): II. Current and historic epidemiologic studies. J Invest Dermatol. 1989;92(1):4–12.CrossRefPubMedGoogle Scholar
  54. 54.
    Metry DW, Hebert AA, Jordon RE. Nonendemic pemphigus foliaceus in children. J Am Acad Dermatol. 2002;46(3):419–22.CrossRefPubMedGoogle Scholar
  55. 55.
    Connelly EA, Aber C, Kleiner G, Nousari C, Charles C, Schachner LA. Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment. Pediatr Dermatol. 2007;24(2):172–6.  https://doi.org/10.1111/j.1525-1470.2007.00369.x.CrossRefPubMedGoogle Scholar
  56. 56.
    Yu BT, Piamphongsant T. Exfoliative type juvenile pemphigus foliaceus: a case report. J Med Assoc Thai. 1987;70(8):471–4.PubMedGoogle Scholar
  57. 57.
    Mlynek A, Bär M, Bauer A, Meurer M. Juvenile pemphigus foliaceus associated with severe nonscarring alopecia. Br J Dermatol. 2009;161(2):472–4.  https://doi.org/10.1111/j.1365-2133.2009.09224.x.CrossRefPubMedGoogle Scholar
  58. 58.
    Geller S, Gat A, Harel A, Mashiah J, Zeeli T, Eming R, et al. Childhood pemphigus foliaceus with exclusive immunoglobulin G autoantibodies to desmocollins. Pediatr Dermatol. 2016;33(1):e10–3.  https://doi.org/10.1111/pde.12729.CrossRefPubMedGoogle Scholar
  59. 59.
    Laarman R, Horii KA. Concurrent pemphigus foliaceus and graves’ disease. Pediatr Dermatol. 2017;34(2):e95–6.  https://doi.org/10.1111/pde.13051.CrossRefPubMedGoogle Scholar
  60. 60.
    Salazar R, Cerghet M, Farhat E, Lim HW. Neuromyelitis optica in a patient with pemphigus foliaceus. J Neurol Sci. 2012;319(1–2):152–5.  https://doi.org/10.1016/j.jns.2012.05.007.CrossRefPubMedGoogle Scholar
  61. 61.
    Perry HO. Pemphigus foliaceus. Arch Dermatol. 1961;83:52–72.CrossRefPubMedGoogle Scholar
  62. 62.
    Adah A, Hill K, Wyatt J, Didion L. Pemphigus foliaceus in an adolescent. J Pediatr. 2014;165(5):1062.e1061.  https://doi.org/10.1016/j.jpeds.2014.07.023.CrossRefGoogle Scholar
  63. 63.
    Loh TY, Paravar T. Rituximab in the management of juvenile pemphigus foliaceus. Dermatol Online J. 2017;23(6). Retrieved from https://escholarship.org/uc/item/0415n1r5.
  64. 64.
    Herr AL, Hatami A, Kokta V, Dalle JH, Champagne MA, Duval M. Successful anti-CD20 antibody treatment of pemphigus foliaceus after unrelated cord blood transplantation. Bone Marrow Transpl. 2005;35(4):427–8.  https://doi.org/10.1038/sj.bmt.1704808.CrossRefGoogle Scholar
  65. 65.
    Mimouni D, Anhalt GJ, Lazarova Z, Aho S, Kazerounian S, Kouba DJ, et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol. 2002;147(4):725–32.CrossRefPubMedGoogle Scholar
  66. 66.
    Han SP, Fu LS, Chen LJ. Masked pemphigus among pediatric patients with Castleman’s disease. Int J Rheum Dis. 2019;22(1):121–31.  https://doi.org/10.1111/1756-185x.13407.CrossRefPubMedGoogle Scholar
  67. 67.
    Ohzono A, Sogame R, Li X, Teye K, Tsuchisaka A, Numata S, et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015;173(6):1447–52.  https://doi.org/10.1111/bjd.14162.CrossRefPubMedGoogle Scholar
  68. 68.
    Tsuchisaka A, Numata S, Teye K, Natsuaki Y, Kawakami T, Takeda Y, et al. Epiplakin is a paraneoplastic pemphigus autoantigen and related to bronchiolitis obliterans in Japanese patients. J Invest Dermatol. 2016;136(2):399–408.  https://doi.org/10.1038/JID.2015.408.CrossRefPubMedGoogle Scholar
  69. 69.
    Daneshpazhooh M, Moeineddin F, Kiani A, Naraghi ZS, Firooz A, Akhyani M, et al. Fatal paraneoplastic pemphigus after removal of Castleman’s disease in a child. Pediatr Dermatol. 2012;29(5):656–7.  https://doi.org/10.1111/j.1525-1470.2011.01670.x.CrossRefPubMedGoogle Scholar
  70. 70.
    Waisbourd-Zinman O, Ben-Amitai D, Cohen AD, Feinmesser M, Mimouni D, Adir-Shani A, et al. Bullous pemphigoid in infancy: clinical and epidemiologic characteristics. J Am Acad Dermatol. 2008;58(1):41–8.  https://doi.org/10.1016/j.jaad.2007.08.010.CrossRefPubMedGoogle Scholar
  71. 71.
    Das D, Bandyopadhyay D. Juvenile pemphigoid nodularis: report of a rare case. Indian Dermatol Online J. 2014;5(2):189–92.  https://doi.org/10.4103/2229-5178.131101.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    McGinness JL, Bivens MM, Greer KE, Patterson JW, Saulsbury FT. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature. J Am Acad Dermatol. 2006;55(1):143–8.  https://doi.org/10.1016/j.jaad.2005.08.047.CrossRefPubMedGoogle Scholar
  73. 73.
    Ratnavel RC, Shanks AJ, Grant JW, Norris PG. Juvenile pemphigoid nodularis. Br J Dermatol. 1994;130(1):125–6.CrossRefPubMedGoogle Scholar
  74. 74.
    Khatib Y, Makhija M, Patel RD, Karad G. Pemphigoid vegetans in childhood: a case report and short review of literature. Indian J Dermatol. 2015;60(4):422.  https://doi.org/10.4103/0019-5154.160534.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Dayal S, Sahu P, Jain VK. Dyshidrosiform pemphigoid localized on the hands in a child: a rare occurrence. An Bras Dermatol. 2017;92(5):714–6.  https://doi.org/10.1590/abd1806-4841.20174949.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Yamane N, Sawamura D, Nishie W, Abe M, Kodama K, Adachi K, et al. Anti-p200 pemphigoid in a 17-year-old girl successfully treated with systemic corticosteroid and dapsone. Br J Dermatol. 2007;156(5):1075–8.  https://doi.org/10.1111/j.1365-2133.2007.07810.x.CrossRefPubMedGoogle Scholar
  77. 77.
    Mammen C, White CT, Prendiville J. Childhood bullous pemphigoid: a rare manifestation of chronic renal allograft rejection. J Am Acad Dermatol. 2011;65(1):217–9.  https://doi.org/10.1016/j.jaad.2010.02.034.CrossRefPubMedGoogle Scholar
  78. 78.
    de la Fuente S, Hernández-Martín Á, de Lucas R, González-Enseñat MA, Vicente A, Colmenero I, et al. Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review. Pediatr Dermatol. 2013;30(6):741–4.  https://doi.org/10.1111/pde.12231.CrossRefPubMedGoogle Scholar
  79. 79.
    Muramatsu K, Ujiie H, Kobayashi I, Nishie W, Izumi K, Ito T, et al. Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects. J Allergy Clin Immunol. 2018;142(6):1818–30.  https://doi.org/10.1016/j.jaci.2018.03.014 (e1816).CrossRefPubMedGoogle Scholar
  80. 80.
    Hashimoto T, Takahashi H, Sakaguchi S. Regulatory T-cell deficiency and autoimmune skin disease: beyond the scurfy mouse and immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. J Allergy Clin Immunol. 2018;142(6):1754–6.  https://doi.org/10.1016/j.jaci.2018.08.028.CrossRefPubMedGoogle Scholar
  81. 81.
    Gajic-Veljic M, Nikolic M, Medenica L. Juvenile bullous pemphigoid: the presentation and follow-up of six cases. J Eur Acad Dermatol Venereol. 2010;24(1):69–72.  https://doi.org/10.1111/j.1468-3083.2009.03264.x.CrossRefPubMedGoogle Scholar
  82. 82.
    Trüeb RM, Didierjean L, Fellas A, Elias A, Borradori L. Childhood bullous pemphigoid: report of a case with characterization of the targeted antigens. J Am Acad Dermatol. 1999;40(2 Pt 2):338–44.CrossRefPubMedGoogle Scholar
  83. 83.
    Seminario-Vidal L, Sami N, Miller J, Theos A. Mycophenolate mofetil therapy for pediatric bullous pemphigoid. Dermatol Online J. 2015;21(8). Retrieved from https://escholarship.org/uc/item/3x5585zn.
  84. 84.
    Tekin B, Yücelten AD. Infantile bullous pemphigoid treated using intravenous immunoglobulin: case report and review of the literature. Pediatr Dermatol. 2015;32(5):723–6.  https://doi.org/10.1111/pde.12635.CrossRefPubMedGoogle Scholar
  85. 85.
    Tripodi G, Risso M, Tenerini L, Gandullia P, Castellano E, Rivabella L. Drug-resistant bullous pemphigoid and inflammatory bowel disease in a pediatric case successfully treated by plasma exchange and extracorporeal photochemotherapy. J Clin Apher. 2007;22(1):26–30.  https://doi.org/10.1002/jca.20115.CrossRefPubMedGoogle Scholar
  86. 86.
    Fuertes I, Luelmo J, Leal L, Romaní J, Sánchez S, Mascaró JM. Refractory childhood pemphigoid successfully treated with rituximab. Pediatr Dermatol. 2013;30(5):e96–7.  https://doi.org/10.1111/pde.12057.CrossRefPubMedGoogle Scholar
  87. 87.
    Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transpl. 2002;30(5):327–9.  https://doi.org/10.1038/sj.bmt.1703654.CrossRefGoogle Scholar
  88. 88.
    Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156(2):352–6.  https://doi.org/10.1111/j.1365-2133.2006.07646.x.CrossRefPubMedGoogle Scholar
  89. 89.
    Kharfi M, Khaled A, Anane R, Fazaa B, Kamoun MR. Early onset childhood cicatricial pemphigoid: a case report and review of the literature. Pediatr Dermatol. 2010;27(2):119–24.  https://doi.org/10.1111/j.1525-1470.2009.01079.x.CrossRefPubMedGoogle Scholar
  90. 90.
    Kahn E, Spence Shishido A, Yancey KB, Lawley LP. Anti-laminin-332 mucous membrane pemphigoid in a 9-year old girl. Pediatr Dermatol. 2014;31(3):e76–9.  https://doi.org/10.1111/pde.12210.CrossRefPubMedGoogle Scholar
  91. 91.
    Rose C, Schmidt E, Kerstan A, Thoma-Uszynski S, Wesselmann U, Käsbohrer U, et al. Histopathology of anti-laminin 5 mucous membrane pemphigoid. J Am Acad Dermatol. 2009;61(3):433–40.  https://doi.org/10.1016/j.jaad.2009.02.012.CrossRefPubMedGoogle Scholar
  92. 92.
    Tavakolpour S. The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: a review of literature. J Res Med Sci. 2016;21:37.  https://doi.org/10.4103/1735-1995.183992.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Maley A, Warren M, Haberman I, Swerlick R, Kharod-Dholakia B, Feldman R. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol. 2016;74(5):835–40.  https://doi.org/10.1016/j.jaad.2016.01.020.CrossRefPubMedGoogle Scholar
  94. 94.
    Mayuzumi M, Akiyama M, Nishie W, Ukae S, Abe M, Sawamura D, et al. Childhood epidermolysis bullosa acquisita with autoantibodies against the noncollagenous 1 and 2 domains of type VII collagen: case report and review of the literature. Br J Dermatol. 2006;155(5):1048–52.  https://doi.org/10.1111/j.1365-2133.2006.07443.x.CrossRefPubMedGoogle Scholar
  95. 95.
    Yang B, Wang C, Wang N, Pan F, Chen S, Zhou G, et al. Childhood epidermolysis bullosa acquisita: report of a Chinese case. Pediatr Dermatol. 2012;29(5):614–7.  https://doi.org/10.1111/j.1525-1470.2011.01509.x.CrossRefPubMedGoogle Scholar
  96. 96.
    Abrams ML, Smidt A, Benjamin L, Chen M, Woodley D, Mancini AJ. Congenital epidermolysis bullosa acquisita: vertical transfer of maternal autoantibody from mother to infant. Arch Dermatol. 2011;147(3):337–41.  https://doi.org/10.1001/archdermatol.2010.317.CrossRefPubMedGoogle Scholar
  97. 97.
    Guerra L, Pacifico V, Calabresi V, De Luca N, Castiglia D, Angelo C, et al. Childhood epidermolysis bullosa acquisita during squaric acid dibutyl ester immunotherapy for alopecia areata. Br J Dermatol. 2017;176(2):491–4.  https://doi.org/10.1111/bjd.14764.CrossRefPubMedGoogle Scholar
  98. 98.
    Tran MM, Anhalt GJ, Barrett T, Cohen BA. Childhood IgA-mediated epidermolysis bullosa acquisita responding to mycophenolate mofetil as a corticosteroid-sparing agent. J Am Acad Dermatol. 2006;54(4):734–6.  https://doi.org/10.1016/j.jaad.2005.07.009.CrossRefPubMedGoogle Scholar
  99. 99.
    Bauer JW, Schaeppi H, Metze D, Muss W, Pohla-Gubo G, Hametner R, et al. Ocular involvement in IgA-epidermolysis bullosa acquisita. Br J Dermatol. 1999;141(5):887–92.CrossRefPubMedGoogle Scholar
  100. 100.
    Caux F, Kirtschig G, Lemarchand-Venencie F, Venencie PY, Hoang-Xuan T, Robin H, et al. IgA-epidermolysis bullosa acquisita in a child resulting in blindness. Br J Dermatol. 1997;137(2):270–5.CrossRefPubMedGoogle Scholar
  101. 101.
    Fine JD, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW, Has C, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103–26.  https://doi.org/10.1016/j.jaad.2014.01.903.CrossRefPubMedGoogle Scholar
  102. 102.
    Stouthamer A, Nieboer C, van der Waal RI, Jonkman MF. Normal expression of the 19-DEJ-1 epitope in two siblings with late-onset junctional epidermolysis bullosa. Br J Dermatol. 2001;144(5):1054–7.CrossRefPubMedGoogle Scholar
  103. 103.
    Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986–2006. J Am Acad Dermatol. 2009;60(2):203–11.  https://doi.org/10.1016/j.jaad.2008.09.035.CrossRefPubMedGoogle Scholar
  104. 104.
    Rashidghamat E, McGrath JA. Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa. Intractable Rare Dis Res. 2017;6(1):6–20.  https://doi.org/10.5582/irdr.2017.01005.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Yang CS, Kim C, Antaya RJ. Review of thalidomide use in the pediatric population. J Am Acad Dermatol. 2015;72(4):703–11.  https://doi.org/10.1016/j.jaad.2015.01.002.CrossRefPubMedGoogle Scholar
  106. 106.
    Takahashi T, Mizutani Y, Ito M, Nakano H, Sawamura D, Seishima M. Dystrophic epidermolysis bullosa pruriginosa successfully treated with immunosuppressants. J Dermatol. 2016;43(11):1391–2.  https://doi.org/10.1111/1346-8138.13406.CrossRefPubMedGoogle Scholar
  107. 107.
    Tarutani M, Shiga T, Nakajima K, Nakano H, Sawamura D, Sano S. Dystrophic epidermolysis bullosa pruriginosa in a mother and daughter successfully treated by low dose cyclosporine. Eur J Dermatol. 2013;23(5):727–9.  https://doi.org/10.1684/ejd.2013.2126.CrossRefPubMedGoogle Scholar
  108. 108.
    Yamasaki H, Tada J, Yoshioka T, Arata J. Epidermolysis bullosa pruriginosa (McGrath) successfully controlled by oral cyclosporin. Br J Dermatol. 1997;137(2):308–10.PubMedGoogle Scholar
  109. 109.
    Fine JD, Johnson LB, Weiner M, Stein A, Suchindran C. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase 1 trial of systemic isotretinoin. J Am Acad Dermatol. 2004;50(4):563–71.  https://doi.org/10.1016/j.jaad.2003.08.008.CrossRefPubMedGoogle Scholar
  110. 110.
    Cheng DR, Barton R, Greenway A, Crawford NW. Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients. Expert Rev Vaccines. 2016;15(12):1567–74.  https://doi.org/10.1080/14760584.2016.1193438.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of MinnesotaMinneapolisUSA
  2. 2.Department of Internal MedicineUniversity of MinnesotaMinneapolisUSA
  3. 3.Department of PediatricsUniversity of MinnesotaMinneapolisUSA

Personalised recommendations